Eli Lilly (LLY) Research & Development (2009 - 2026)
Eli Lilly posted quarterly Research & Development of $3.5 billion for Q1 2026, up 28.38% year-on-year from $2.7 billion in Q1 2025, and down 7.67% on a QoQ basis from $3.8 billion in Q4 2025.
Eli Lilly (LLY) has 18 years of Research & Development data on file, last reported at $3.5 billion in Q1 2026.
- For the quarter ending Q1 2026, Research & Development rose 28.38% year-over-year to $3.5 billion; the trailing twelve-month figure through Mar 2026 stood at $14.1 billion (up 25.99% YoY), and the FY2025 full-year result was $13.3 billion, up 21.34% from the prior year.
- Research & Development for Q1 2026 stood at $3.5 billion, down from $3.8 billion in the prior quarter.
- Across five years, Research & Development topped out at $3.8 billion in Q4 2025 and bottomed at $1.6 billion in Q1 2022.
- The 5-year median for Research & Development is $2.6 billion (2023), against an average of $2.6 billion.
- The widest annual swing landed in 2022, when Research & Development dropped 3.71%; it then jumped 33.62% in 2023.
- A 5-year view of Research & Development shows it stood at $2.0 billion in 2022, then grew by 28.38% to $2.6 billion in 2023, then increased by 17.98% to $3.0 billion in 2024, then climbed by 25.76% to $3.8 billion in 2025, then dropped by 7.67% to $3.5 billion in 2026.
- The last three Research & Development figures came in at $3.5 billion (Q1 2026), $3.8 billion (Q4 2025), and $3.5 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 3.51 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 3.53 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 2.47 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 12.59 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 1.72 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 1.37 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 2.49 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 2.65 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.51 Bn |
| Dec 31, 2025 | 3.80 Bn |
| Sep 30, 2025 | 3.47 Bn |
| Jun 30, 2025 | 3.34 Bn |
| Mar 31, 2025 | 2.73 Bn |
| Dec 31, 2024 | 3.02 Bn |
| Sep 30, 2024 | 2.73 Bn |
| Jun 30, 2024 | 2.71 Bn |
| Mar 31, 2024 | 2.52 Bn |
| Dec 31, 2023 | 2.56 Bn |
| Sep 30, 2023 | 2.41 Bn |
| Jun 30, 2023 | 2.36 Bn |
| Mar 31, 2023 | 1.99 Bn |
| Dec 31, 2022 | 2.00 Bn |
| Sep 30, 2022 | 1.80 Bn |
| Jun 30, 2022 | 1.78 Bn |
| Mar 31, 2022 | 1.61 Bn |
| Dec 31, 2021 | 1.90 Bn |
| Sep 30, 2021 | 1.71 Bn |
| Jun 30, 2021 | 1.66 Bn |
| Mar 31, 2021 | 1.67 Bn |
| Dec 31, 2020 | 1.73 Bn |
| Sep 30, 2020 | 1.47 Bn |
| Jun 30, 2020 | 1.39 Bn |
| Mar 31, 2020 | 1.39 Bn |
| Dec 31, 2019 | 1.58 Bn |
| Sep 30, 2019 | 1.38 Bn |
| Jun 30, 2019 | 1.40 Bn |
| Mar 31, 2019 | 1.23 Bn |
| Dec 31, 2018 | 1.39 Bn |
| Sep 30, 2018 | 1.28 Bn |
| Jun 30, 2018 | 1.27 Bn |
| Mar 31, 2018 | 1.11 Bn |
| Dec 31, 2017 | 1.23 Bn |
| Sep 30, 2017 | 1.34 Bn |
| Jun 30, 2017 | 1.27 Bn |
| Mar 31, 2017 | 1.26 Bn |
| Dec 31, 2016 | -3.74 Bn |
| Sep 30, 2016 | 1.24 Bn |
| Jun 30, 2016 | 1.34 Bn |
| Mar 31, 2016 | 55.00 Mn |
| Dec 31, 2015 | 1.44 Bn |
| Sep 30, 2015 | 1.14 Bn |
| Jun 30, 2015 | 1.17 Bn |
| Mar 31, 2015 | 1.04 Bn |
| Dec 31, 2014 | 1.19 Bn |
| Sep 30, 2014 | 1.24 Bn |
| Jun 30, 2014 | 1.20 Bn |
| Mar 31, 2014 | 1.11 Bn |
| Dec 31, 2013 | 1.48 Bn |
| Sep 30, 2013 | 1.38 Bn |
| Jun 30, 2013 | 1.33 Bn |
| Mar 31, 2013 | 1.35 Bn |
| Dec 31, 2012 | 1.46 Bn |
| Sep 30, 2012 | 1.34 Bn |
| Jun 30, 2012 | 1.32 Bn |
| Mar 31, 2012 | 1.15 Bn |
| Dec 31, 2011 | 1.36 Bn |
| Sep 30, 2011 | 1.28 Bn |
| Jun 30, 2011 | 1.26 Bn |
| Mar 31, 2011 | 1.12 Bn |
| Dec 31, 2010 | 1.44 Bn |
| Sep 30, 2010 | 1.22 Bn |
| Jun 30, 2010 | 1.19 Bn |
| Mar 31, 2010 | 1.04 Bn |
| Dec 31, 2009 | 1.22 Bn |
| Sep 30, 2009 | 1.12 Bn |
| Jun 30, 2009 | 1.04 Bn |
| Mar 31, 2009 | 947.30 Mn |